Circulating Levels of Irisin in Hypopituitary and Normal Subjects

PLoS One. 2016 Jul 29;11(7):e0160364. doi: 10.1371/journal.pone.0160364. eCollection 2016.

Abstract

Context: The recently identified myokine irisin conveys some of the benefits of exercise. Hypopituitarism with adult growth hormone deficiency (HP) is a situation characterized by decreased GH secretion and an altered body composition.

Objective: Our aim was to study the skeletal muscle hormone irisin in HP, and compare the results with a similar group of normal subjects.

Participants and methods: Seventeen HP patients and fifty-one normal subjects of similar age and sex were studied. The diagnosis of GH deficiency was confirmed by the presence of pituitary disease and a peak GH secretion below 3 μg/L after an insulin tolerance test. The patients were adequately treated for all pituitary hormone deficits, except for GH. Fasting serum irisin was measured with an enzyme immunoassay, and HOMA-IR, QUICKI and HOMA-β were calculated.

Results: Fasting irisin levels (ng/ml) were similar in normal [208.42 (168.44-249.23)] and HP patients [195.13 (178.44-241.44)]. In the control group there were moderate significant positive correlations between irisin and BMI, waist circumference, leptin, fasting insulin, HOMA-IR, HOMA-β, triglycerides, and cholesterol. In the control group there were moderate significant negative correlations between irisin and IGF-I and QUICKI. In the hypopituitary group there were moderate significant positive correlations between irisin and body fat and HOMA-β.

Conclusions: We found similar irisin levels in GH deficiency hypopituitary patients when compared with normal subjects. The correlation between irisin and adiposity related factors suggests that that in the case of this clinical model, irisin is regulated by adiposity and not by GH.

MeSH terms

  • Adult
  • Case-Control Studies
  • Female
  • Fibronectins / blood*
  • Humans
  • Hypopituitarism / blood*
  • Male
  • Middle Aged
  • Muscle, Skeletal / metabolism

Substances

  • FNDC5 protein, human
  • Fibronectins

Grants and funding

This work was supported in part by FIS del Instituto de Salud Carlos III PI10/00088, PI13/00322 (FEDER from E.U.) and Xunta de Galicia IN845B-2010/187, 10CSA916014PR, CN2012/312, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.